X4 Pharmaceuticals Reports Second Quarter 2024 Financial Results and Provides Corporate Updates
First
Positive interim data from Phase 2 trial of mavorixafor in chronic neutropenia; full trial results expected in
Initiated global, pivotal Phase 3 trial of mavorixafor in chronic neutropenia
Conference call to be hosted today at
Recent and Key Anticipated Upcoming Milestones
XOLREMDI™ (mavorixafor) in WHIM Syndrome, a Rare Primary Immunodeficiency:
- FDA Approval of XOLREMDI. In
April 2024 , X4 announced that theU.S. Food and Drug Administration (FDA) approved XOLREMDI™ (mavorixafor) capsules for use in patients 12 years of age and older with WHIM syndrome (warts, hypogammaglobulinemia, infections and myelokathexis) to increase the number of circulating mature neutrophils and lymphocytes. U.S. Launch Update: X4 is currently executing itsU.S. launch of XOLREMDI and generating its first revenues from product sales. Launch efforts have included: increasing interactions with targeted physicians and rare disease patient advocacy groups, continuing disease awareness and education campaigns, and activating its X4Connect™ and nurse educator programs, which provide a suite of patient support services.- 4WHIM Phase 3
Data Publications . During the second quarter of 2024, data from the company’s completed global, pivotal Phase 3 4WHIM clinical trial were published online in Blood, the journal of theAmerican Society of Hematology (ASH), and new data from the trial and its open-label extension phase were presented at the annual meeting of theClinical Immunological Society (CIS). - Maximizing the Global Opportunity in WHIM Syndrome. X4 currently expects to submit for regulatory approval of mavorixafor in WHIM syndrome from the
European Medicines Agency (EMA) by early 2025, while also exploring additional potential opportunities in geographies where the company may be able to efficiently leverage itsU.S. FDA approval.
Advancing Mavorixafor in Chronic Neutropenic Disorders:
- Positive Interim Phase 2 Clinical Data. In
June 2024 , X4 presented positive clinical data from its ongoing Phase 2 clinical trial evaluating the safety and efficacy of mavorixafor in the treatment of people with chronic neutropenia (CN). The interim results showed that once-daily oral mavorixafor was generally well tolerated and durably increased participants’ absolute neutrophil counts (ANC) both as a monotherapy and in combination with stable doses of injectable granulocyte colony-stimulating factor (G-CSF), the only therapy approved in theU.S. for severe chronic neutropenia. - Full Phase 2 Data Expected in
November 2024 . Data from the completed Phase 2 CN trial, including data from the group of participants receiving mavorixafor and dose-adjusted G-CSF, are expected to be presented inNovember 2024 . - Initiation of Phase 3 4WARD Trial. In
June 2024 , the company also announced the initiation of its global, pivotal Phase 3 clinical trial (NCT06056297), evaluating the efficacy, safety, and tolerability of oral, once-daily mavorixafor (with or without stable doses of G-CSF) in people with congenital, acquired primary autoimmune, or idiopathic CN who are experiencing recurrent and/or serious infections. The 52-week 4WARD trial is a randomized, double-blind, placebo-controlled, multicenter study aiming to enroll 150 participants.
Second Quarter 2024 Financial Results
- Gain on Sale of Non-Financial Asset: In
May 2024 , X4 recognized a gain on the sale of a priority review voucher (PRV) to a third party for$105.0 million in cash. The PRV was awarded to X4 by the FDA under its Rare Pediatric Disease program upon the approval of XOLREMDI. Under this program, the FDA awards PRVs to sponsors of rare pediatric disease product applications that meet certain criteria to encourage development of new drugs and biologics for the prevention and treatment of rare pediatric diseases. - Cash, Cash Equivalents,
Restricted Cash and Short-Term Marketable Securities : X4 had$169.5 million in cash, cash equivalents, restricted cash, and short-term marketable securities as ofJune 30, 2024 . X4 believes it has sufficient funds to support company operations into late 2025 and notes that this projected runway does not include potential future XOLREMDI revenue. - Revenue and Cost of Revenue: For the three months ended
June 30, 2024 , X4 reported net product revenue of$0.6 million and cost of revenue of$0.3 million related to the sale of XOLREMDI. Cost of revenue includes approximately$0.2 million of license costs, including sale-based royalties and operational milestones capitalized as an intangible asset and amortized over the life of the underlying intellectual property. X4 did not report product revenue or cost of revenue in any prior period. - Research and Development (R&D) Expenses were
$20.9 million for the second quarter endedJune 30, 2024 as compared to$15.6 million for the comparable period in 2023. R&D expenses for the second quarter endedJune 30, 2024 included$1.2 million of certain non-cash expenses. - Selling, General, and Administrative Expenses (SG&A) were
$13.3 million for the second quarter endedJune 30, 2024 as compared to$10.2 million for the comparable period in 2023. SG&A expenses for the second quarter endedJune 30, 2024 included$1.2 million of certain non-cash expenses. - Net Income (Loss): X4 reported net income of
$90.8 million for the second quarter endedJune 30, 2024 , as compared to a net loss of$55.7 million for the comparable period in 2023. Net income in the current period includes the sale of a PRV for$105.0 million , as noted above, and a non-cash gain of$20.2 million related to the fair value remeasurement of the company’s Class C warrant liability.
Conference Call and Webcast
X4 will host a conference call and webcast today at
About XOLREMDI™ (mavorixafor)
XOLREMDI (mavorixafor) is a selective CXCR4 receptor antagonist approved in the
About WHIM Syndrome
WHIM syndrome is a rare, combined primary immunodeficiency and chronic neutropenic disorder caused by CXCR4 receptor dysfunction that results in impaired mobilization of white blood cells from the bone marrow into peripheral circulation. WHIM syndrome is named for its four classic manifestations: warts, hypogammaglobulinemia, infections, and myelokathexis, although only a minority of patients experience all four manifestations in the acronym. People with WHIM syndrome characteristically have low blood levels of neutrophils (neutropenia) and lymphocytes (lymphopenia), and as a result, experience serious and/or frequent infections.
About Chronic Neutropenia and Mavorixafor
Chronic neutropenia is a rare blood condition lasting more than three months, persistently or intermittently, and characterized by increased risk of infections and reduced quality of life due to abnormally low levels of neutrophils circulating in the blood. Neutrophils are retained in the bone marrow by the CXCR4/CXCL12 axis, creating a reserve of cells. Downregulation of the CXCR4 receptor by mavorixafor, an orally active CXCR4 antagonist, has been shown to mobilize neutrophils from the bone marrow into the peripheral blood across multiple disease states. The level of circulating neutrophils is typically measured by drawing blood to determine the absolute neutrophil count (ANC).
About the 4WARD Global, Pivotal, Phase 3 Clinical Trial
The 4WARD trial is a global, pivotal Phase 3 clinical trial (NCT06056297) evaluating the efficacy, safety, and tolerability of oral, once-daily mavorixafor (with or without G-CSF) in people with congenital, acquired primary autoimmune, or idiopathic chronic neutropenia who are experiencing recurrent and/or serious infections. The 52-week trial is a randomized, double-blind, placebo-controlled, multicenter study aiming to enroll 150 participants with confirmed trough ANC levels less than 1,500 cells per microliter at baseline screening and histories of two or more serious and/or recurrent infections in the prior year. The primary endpoint of the trial is based on two outcome measures: annualized infection rate and positive ANC response.
About
X4 is delivering progress for patients by developing and commercializing innovative therapies for those with rare diseases of the immune system and significant unmet needs. Leveraging our expertise in CXCR4 and immune system biology, we have successfully developed mavorixafor, which has received
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of applicable securities laws, including the Private Securities Litigation Reform Act of 1995, as amended. These statements may be identified by the words “may,” “will,” “could,” “would,” “should,” “expect,” “plan,” “anticipate,” “intend,” “believe,” “estimate,” “predict,” “project,” “potential,” “continue,” “target,” or other similar terms or expressions that concern X4's expectations, strategy, plans, or intentions. Forward-looking statements include, without limitation, implied or express statements regarding X4’s expected cash runway; X4’s commercialization plans and ongoing efforts with respect to XOLREMDI and the expected timing thereof; and other statements regarding X4’s future operations, financial performance, financial position, prospects, objectives and other future events; the potential therapeutic benefit of mavorixafor; the initiation, timing, progress, and results of our current and future studies and clinical trials, including the Phase 2 clinical trial in chronic neutropenia and the Phase 3 4WARD clinical trial and related preparatory work and the period during which the results of the trials will become available; and the mission and goals for our business. Any forward-looking statements in this press release are based on management's current expectations and beliefs. These forward-looking statements are neither promises nor guarantees of future performance, and are subject to a variety of risks and uncertainties, many of which are beyond X4’s control, which could cause actual results to differ materially from those contemplated in these forward-looking statements, including, without limitation, the risks that: unanticipated costs and expenses may be greater than anticipated; X4’s cash and cash equivalents may not be sufficient to support its operating plan for as long as anticipated; delays, interruptions or failures in the manufacture and supply of X4’s products; X4’s ability to obtain additional funding to support its clinical development and commercial programs; we may encounter adverse events for mavorixafor at any stage that negatively impact development and/or commercialization; the expected availability, content, and timing of clinical data from our ongoing clinical trials of mavorixafor may be delayed or unavailable, including clinical results from our ongoing Phase 2 clinical trial and the announced Phase 3 4WARD trial; the trials and studies may not have satisfactory outcomes; the outcomes of preclinical studies or earlier clinical trials will not be predictive of later clinical trial results; the design and rate of enrollment for clinical trials, including the current design of our Phase 3 clinical trial evaluating mavorixafor in certain chronic neutropenic disorders may not enable successful completion of the trial(s); we may be unable to obtain and maintain regulatory approvals; uncertainties inherent in the initiation and completion of preclinical studies and clinical trials and clinical development; there will be changes in expected or existing competition; there will be changes in the regulatory environment; our business may be adversely affected and our costs may increase if any of our key collaborators fails to perform its obligations or terminates our collaboration; the internal and external costs required for our ongoing and planned activities, and the resulting impact on expense and use of cash, may be higher than expected which may cause us to use cash more quickly than we expect or to change or curtail some of our plans or both; and other risks and uncertainties, including those described in the section entitled “Risk Factors” in X4’s Annual Report on Form 10-Q filed with the
(Tables Follow)
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (in thousands, except per share amounts) (unaudited) |
|||||||||||||||
| Three Months Ended | Six Months Ended | ||||||||||||||
| 2024 | 2023 | 2024 | 2023 | ||||||||||||
| Product revenue, net | $ | 563 | $ | — | $ | 563 | $ | — | |||||||
| Costs and operating expenses: | |||||||||||||||
| Cost of revenue | 268 | — | 268 | — | |||||||||||
| Research and development | 20,914 | 15,601 | 40,768 | 37,664 | |||||||||||
| Selling, general and administrative | 13,278 | 10,204 | 30,713 | 17,445 | |||||||||||
| Gain on sale of non-financial asset | (105,000 | ) | — | (105,000 | ) | — | |||||||||
| Total operating (income) expense | (70,540 | ) | 25,805 | (33,251 | ) | 55,109 | |||||||||
| Income (loss) from operations | 71,103 | (25,805 | ) | 33,814 | (55,109 | ) | |||||||||
| Other income (expense), net: | 19,748 | (29,892 | ) | 5,290 | (24,604 | ) | |||||||||
| Income (loss) before provision for income taxes | 90,851 | (55,697 | ) | 39,104 | (79,713 | ) | |||||||||
| Provision for income taxes | 18 | 15 | 37 | 19 | |||||||||||
| Net income (loss) | $ | 90,833 | $ | (55,712 | ) | $ | 39,067 | $ | (79,732 | ) | |||||
| Net income (loss) per share: basic | $ | 0.45 | $ | (0.33 | ) | $ | 0.20 | $ | (0.51 | ) | |||||
| Weighted average shares--basic | 200,440 | 168,738 | 200,216 | 157,416 | |||||||||||
| Net income (loss) per share: diluted | $ | 0.45 | $ | (0.33 | ) | $ | 0.19 | $ | (0.51 | ) | |||||
| Weighted average shares--diluted | 200,801 | 168,738 | 200,456 | 157,416 | |||||||||||
CONDENSED CONSOLIDATED BALANCE SHEETS (in thousands) (unaudited) |
|||||
| Current assets: | |||||
| Cash and cash equivalents | $ | 147,218 | $ | 99,216 | |
| Marketable securities | 21,536 | 15,000 | |||
| Research and development incentive receivable | 854 | 562 | |||
| Inventory | 831 | — | |||
| Prepaid expenses and other current assets | 4,977 | 7,298 | |||
| Total current assets | 175,416 | 122,076 | |||
| Property and equipment, net | 808 | 745 | |||
| Goodwill | 17,351 | 17,351 | |||
| Intangible asset, net | 10,375 | — | |||
| Right-of-use assets | 4,872 | 5,650 | |||
| Other assets | 1,789 | 1,436 | |||
| Total assets | $ | 210,611 | $ | 147,258 | |
| Current liabilities: | |||||
| Accounts payable | $ | 7,986 | $ | 8,947 | |
| Accrued expenses | 19,744 | 12,816 | |||
| Current portion of lease liability | 1,172 | 1,099 | |||
| Total current liabilities | 28,902 | 22,862 | |||
| Long-term debt, including accretion, net of discount | 75,030 | 54,570 | |||
| Lease liabilities | 2,026 | 2,612 | |||
| Warrant liability | 9,223 | 15,683 | |||
| Other liabilities | 979 | 432 | |||
| Total liabilities | 116,160 | 96,159 | |||
| Total stockholders' equity | 94,451 | 51,099 | |||
| Total liabilities and stockholders' equity | $ | 210,611 | $ | 147,258 | |
Company Contact:
Head of Corporate & Patient Affairs
jose.juves@x4pharma.com
Investor Contact:
Managing Director,
daniel@lifesciadvisors.com
(617) 430-7576
Source: X4 Pharmaceuticals